Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma
| العنوان: | Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma |
|---|---|
| المؤلفون: | Rachael R. Schulte, Sara L. Van Driest, C. Michael Stein, Leena Choi, Richard H. Ho, Nipun Utreja |
| المصدر: | Clinical and Translational Science Clinical and Translational Science, Vol 14, Iss 1, Pp 343-353 (2021) |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, 030213 general clinical medicine, Pharmacogenomic Variants, 030226 pharmacology & pharmacy, Gastroenterology, 0302 clinical medicine, General Pharmacology, Toxicology and Pharmaceutics, Young adult, Child, biology, medicine.diagnostic_test, Liver-Specific Organic Anion Transporter 1, lcsh:Public aspects of medicine, General Neuroscience, Articles, General Medicine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Child, Preschool, Female, medicine.drug, Adult, musculoskeletal diseases, Antimetabolites, Antineoplastic, medicine.medical_specialty, Adolescent, Models, Biological, Polymorphism, Single Nucleotide, Article, General Biochemistry, Genetics and Molecular Biology, Young Adult, 03 medical and health sciences, Pharmacokinetics, Internal medicine, medicine, Humans, Dosing, Dose-Response Relationship, Drug, business.industry, Research, lcsh:RM1-950, Body Weight, Lymphoblastic lymphoma, Infant, lcsh:RA1-1270, medicine.disease, Leukemia, Lymphoid, Pharmacogenomic Testing, lcsh:Therapeutics. Pharmacology, Methotrexate, Therapeutic drug monitoring, biology.protein, SLCO1B1, business |
| الوصف: | High‐dose (HD) methotrexate (MTX) is a critical component of treatment for hematologic malignancies in children and young adults. Therapeutic drug monitoring is necessary due to substantial interindividual variation in MTX clearance. Common function‐altering polymorphisms in SLCO1B1 (encodes OATP1B1, which transports MTX) may contribute to clearance variability. We performed pharmacokinetic modeling using data for 106 children and young adults treated with HD MTX for hematologic malignancies; of 396 total courses of HD MTX, 360 consisted of 5 g/m2 over 24 hours. We evaluated the contribution of clinical covariates and SLCO1B1 genotype (388A>G and 521T>C) to MTX clearance variability. Of the clinical covariates studied, patient weight improved the pharmacokinetic model most significantly (P |
| تدمد: | 1752-8062 1752-8054 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72eb3abba07ab7046cb87869cfe4f0d9Test https://doi.org/10.1111/cts.12879Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....72eb3abba07ab7046cb87869cfe4f0d9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17528062 17528054 |
|---|